Gedeon Richter

Gedeon Richter has raised its forecast for adjusted EBIT in 2026 to double-digit growth at constant exchange rates, supported by a strong Vraylar performance and efficiency measures. For the first half of 2026 the company reported pharma sales of HUF 455.2 billion (+8.7% at constant exchange rates) and adjusted EBIT of HUF 151.8 billion (+21% at constant exchange rates) with a margin of 33.3%. The revenue outlook at constant exchange rates remains in the high single digits; AbbVie also raised its Vraylar sales forecast for 2026 to around USD 4.1 billion. » Mere på de.investing.com

Gedeon Richter reports pharma sales of HUF 914 billion for 2025 and a currency-adjusted 14% increase in adjusted EBIT, thereby beating consensus estimates and its own forecast. Drivers were strong quarterly results in biosimilars and women’s health and continued growth of Vraylar; generics showed first signs of recovery in Q4. For 2026 the company expects currency-adjusted high single-digit percentage growth in sales and adjusted EBIT, but notes roughly a 5 percentage-point negative impact from exchange rates. Planned R&D spending is around 11% of sales, and restructuring costs of about €100 million are expected through 2030 for ERP and cloud modernization. » Mere på de.investing.com

Gedeon Richter has revised its 2025 guidance down after weaker nine-month figures and now expects pharmaceutical sales of around €2.3bn and currency-adjusted adjusted EBIT growth of 8–10% (previously around 10%). In the first nine months the company reported pharmaceutical sales of HUF 668.8bn (€1.67bn), adjusted EBIT of HUF 213.1bn and a margin of 31.9%; however, the third quarter showed declines (sales -1.1%, adjusted EBIT -7.3% and earnings per share down 6.9%). Weaker generics and biologics performance, supply-chain issues and currency effects weighed on results, while the CNS segment and women's health grew strongly. » Mere på de.investing.com

Gedeon Richter recorded an 8% currency-adjusted increase in pharmaceutical sales in the first half of 2025, driven by strong performance in the central nervous system and women's health segments. Adjusted EBIT rose by 15%, while earnings per share fell by 13% due to currency effects and higher taxes. The company confirmed its full-year guidance and expects further sales and EBIT growth of around 10% for the year. » Mere på de.investing.com